Related Experiment Videos
Clinical results of the aortic Medtronic-Hall prosthesis
Insights
The Medtronic-Hall aortic valve replacement shows a 97.2% survival rate after two years, with no valve-related deaths or hemolysis. This study suggests the valve is a valuable option for aortic valve surgery.
Area of Science:
- Cardiovascular Surgery
- Biomedical Engineering
Background:
- Aortic valve disease necessitates prosthetic replacement.
- Evaluating the performance of mechanical heart valves is crucial for patient outcomes.
Purpose of the Study:
- To assess the early clinical performance and safety of the Medtronic-Hall aortic prosthesis.
- To report survival rates, thromboembolic events, and hemolysis in patients receiving the valve.
Main Methods:
- Implantation of Medtronic-Hall aortic prostheses in 40 patients between 1979 and 1982.
- Patients received anticoagulant therapy; follow-up ranged from 8 to 39 months.
- Analysis included operative mortality, actuarial survival, thromboembolism, and hemolysis.
Main Results:
- Excluding operative mortality (7.5%), the 2-year actuarial survival rate was 97.2%.
- No deaths were attributed to the valve or its dysfunction.
- The overall thromboembolic rate was 0.78 per 100 patient-years; no episodes occurred in elective surgery patients. No hemolysis was observed.
Conclusions:
- The Medtronic-Hall aortic valve demonstrates promising early clinical results.
- The valve appears valuable, but further long-term studies are required to validate these findings.
Abstract:
Between July 1979 and June 1982 we implanted aortic Medtronic-Hall prostheses in 40 patients. Ages ranged between 25 and 75, with a mean of 56 years. There were 38 cases of elective surgery (group I) and 2 acute aortic dissections (group II). All patients received anticoagulant medication. Follow-up ranged between 8 and 39 months with a mean of 22.5 months. Excluding operative mortality (7.5%) the 2-year actuarial survival rate is 97.2%. No death was related to the valve or its dysfunction. The overall thromboembolic rate is 0.78 per 100 patient years. No thromboembolic episode occurred in group I. No hemolysis was encountered and most patients experienced marked postoperative improvement. We consider that aortic Medtronic-Hall valves are valuable but further studies are necessary to confirm the results we obtained.